

CITATION REPORT

List of articles citing

Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14

DOI: 10.1038/45809

Nature, 1999, 401, 282-6.

Source: <https://exaly.com/paper-pdf/30426504/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
740	The physiological response to cardiovascular 'orphan' G protein-coupled receptor agonists. 1999 , 5, 1241-2		9
739	Structure of a transiently phosphorylated switch in bacterial signal transduction. <i>Nature</i> , 1999 , 402, 894-8	30.4	183
738	Required reading. 1999 , 5, 466		
737	Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14). 1999 , 265, 123-9		204
736	Human Urotensin-II is a Potent Vasoactive Peptide. 2000 , 36, S163-S166		7
735	Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. 2000 , 130, 201-4		134
734	Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. 2000 , 130, 1865-70		144
733	Human urotensin-II is a potent spasmogen of primate airway smooth muscle. 2000 , 131, 10-2		24
732	Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. 2000 , 131, 441-6		206
731	Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. 2000 , 131, 1262-74		186
730	Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. 2000 , 10, 229-37		164
729	Vasodilator effect of urotensin II, one of the most potent vasoconstricting factors, on rat coronary arteries. 2000 , 402, R5-7		60
728	Human urotensin II mediates vasoconstriction via an increase in inositol phosphates. 2000 , 406, 265-71		90
727	Purification and characterization of rat des-Gln14-Ghrelin, a second endogenous ligand for the growth hormone secretagogue receptor. 2000 , 275, 21995-2000		252
726	A G protein-coupled receptor for UDP-glucose. 2000 , 275, 10767-71		254
725	A highly sensitive quantitative cytosensor technique for the identification of receptor ligands in tissue extracts. 2000 , 48, 1553-64		25
724	Assignment of the GPR14 gene coding for the G-protein-coupled receptor 14 to human chromosome 17q25.3 by fluorescent in situ hybridization. 2000 , 88, 312-3		19

723	Mammalian PSP24s (alpha and beta isoforms) are not responsive to lysophosphatidic acid in mammalian expression systems. 2000 , 276, 957-64	17
722	Urotensin II: fish neuropeptide catches orphan receptor. 2000 , 21, 80-2	44
721	Endothelins are potent vasoconstrictors, and much more besides. 2000 , 21, 38-40	25
720	Singular contributions of fish neuroendocrinology to mammalian regulatory peptide research. 2000 , 93, 3-12	30
719	Neuropeptides--an overview. 2000 , 39, 1337-56	458
718	The caudal neurosecretory system: control and function of a novel neuroendocrine system in fish. 2000 , 78, 193-203	42
717	The Sixth International Conference on Endothelin. October 1999, Montreal, Canada. 2000 , 1, 575-9	
716	Drug discovery in the next millennium. 2000 , 40, 177-91	99
715	Cellular and molecular basis of portal hypertension. 2001 , 5, 629-44	57
714	Enhanced stimulation of Akt-3/protein kinase B-gamma in human aortic smooth muscle cells. 2001 , 283, 158-63	36
713	Flow-induced pressure differentially regulates endothelin-1, urotensin II, adrenomedullin, and relaxin in pulmonary vascular endothelium. 2001 , 289, 245-51	53
712	Cloning, pharmacology, and tissue distribution of G-protein-coupled receptor GPR105 (KIAA0001) rodent orthologs. 2001 , 78, 124-8	54
711	Specific expression of the urotensin II gene in sacral motoneurons of developing rat spinal cord. 2001 , 101, 187-90	32
710	Expression of urotensin II and urotensin II receptor mRNAs in various human tumor cell lines and secretion of urotensin II-like immunoreactivity by SW-13 adrenocortical carcinoma cells. 2001 , 22, 1175-9	57
709	Discovery and mapping of ten novel G protein-coupled receptor genes. 2001 , 275, 83-91	145
708	The role of molecular biology in pharmacodynamic research. 2001 , 1220, 161-174	
707	Urotensin II-immunoreactivity in the brainstem and spinal cord of the rat. 2001 , 305, 9-12	61
706	Orphan G-protein-coupled receptors and natural ligand discovery. 2001 , 22, 132-40	202

705	Identification of four novel human G protein-coupled receptors expressed in the brain. 2001 , 86, 13-22	62
704	Orphan G protein-coupled receptors in the CNS. 2001 , 1, 31-9	51
703	Somatostatins and their receptors in fish. 2001 , 129, 543-50	35
702	Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats. 2001 , 508, 57-60	66
701	Human urotensin II increases coronary perfusion pressure in the isolated rat heart: potentiation by nitric oxide synthase and cyclooxygenase inhibition. 2001 , 69, 175-80	44
700	Role of urotensin II in patients on dialysis. 2001 , 358, 810-1	190
699	Urotensin II: a new mediator in cardiopulmonary regulation?. 2001 , 358, 774-5	34
698	Addressing Those Two That Go Together: The Angiotensin II Receptors and their Role in Blood-flow Regulation. 2001 , 10, 6-15	2
697	. 2001 ,	9
696	Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. 2001 , 280, H925-8	123
695	Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. 2001 , 19, 2185-90	197
694	Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation. 2001 , 19, 2191-6	77
693	Eukaryotic Expression. 491-542	
692	Current World Literature. 2001 , 10, 117-160	
691	Central effects of urotensin-II following ICV administration in rats. 2001 , 155, 426-33	69
690	Expression of three vasoactive peptides, urotensin-II, adrenomedullin, and endothelin-1, in a human renal cell carcinoma cell line, VMRC-RCW. 2001 , 5, 246-249	7
689	Comparison of the contractile responses of human coronary bypass grafts and monkey arteries to human urotensin-II. 2001 , 15, 227-31	26
688	Cardiostimulant effects of urotensin-II in human heart in vitro. 2001 , 132, 5-9	108

687	Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats. 2001 , 132, 1625-9	84
686	The urotensin II receptor is expressed in the cholinergic mesopontine tegmentum of the rat. 2001 , 923, 120-7	58
685	Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. 2001 , 104, 16-8	176
684	Biology of the anococcygeus muscle. 2001 , 205, 1-35	16
683	Effects of urotensin II in human arteries and veins of varying caliber. 2001 , 103, 1378-81	83
682	Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. 2001 , 88, 1102-4	236
681	Experimental rupture of atherosclerotic lesions increases distal vascular resistance: a limiting factor to the success of infarct angioplasty. 2002 , 22, 153-60	25
680	Identification of neuropeptide W as the endogenous ligand for orphan G-protein-coupled receptors GPR7 and GPR8. 2002 , 277, 35826-32	125
679	Localization of urotensin-II immunoreactivity in normal human kidneys and renal carcinoma. 2002 , 50, 885-9	95
678	Adrenocortical peptides: autocrine or paracrine regulators for the steroid hormone secretion or the cell proliferation?. 2002 , 110, 373-80	16
677	Novel G-protein-coupled receptor genes expressed in the brain: continued discovery of important therapeutic targets. 2002 , 6, 185-202	13
676	Plasma urotensin in human systolic heart failure. 2002 , 106, 2877-80	138
675	Functional Assays for Identifying Ligands at Orphan G Protein-Coupled Receptors. 2002 , 8, 297-308	4
674	Three vasoactive peptides, endothelin-1, adrenomedullin and urotensin-II, in human tumour cell lines of different origin: expression and effects on proliferation. 2002 , 103 Suppl 48, 35S-38S	20
673	G-protein-coupled receptors in human atherosclerosis: comparison of vasoconstrictors (endothelin and thromboxane) with recently de-orphanized (urotensin-II, apelin and ghrelin) receptors. 2002 , 103 Suppl 48, 171S-175S	40
672	Genetic analysis of G protein-coupled receptor genes. 2002 , 343, 448-59	1
671	Identification of a novel human eicosanoid receptor coupled to G(i/o). 2002 , 277, 31459-65	122
670	Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. 2002 , 45, 1799-805	174

669	Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2-(dimethylamino)ethyl)isochroman-1-one (AC-7954). 2002 , 45, 4950-3	61
668	Urotensin II mediates ERK1/2 phosphorylation and proliferation in GPR14-transfected cell lines. 2002 , 22, 155-68	46
667	Discovery of recently adopted orphan receptors for apelin, urotensin II, and ghrelin identified using novel radioligands and functional role in the human cardiovascular system. 2002 , 80, 369-74	57
666	Congestive heart failure and expression of myocardial urotensin II. 2002 , 359, 1990-7	223
665	Plasma urotensin II in heart failure. 2002 , 360, 545-6	156
664	Involvement of the nitric oxide/L-arginine and sympathetic nervous systems on the vasodepressor action of human urotensin II in anesthetized rats. 2002 , 71, 819-25	24
663	Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. 2002 , 37, 767-72	87
662	Cardiovascular effects of urotensin II in different brain areas. 2002 , 23, 1631-5	53
661	Structural requirements at the N-terminus of urotensin II octapeptides. 2002 , 23, 2259-64	31
660	Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure. 2002 , 110, 33-8	54
659	G protein-coupled receptors: dominant players in cell-cell communication. 2002 , 212, 63-132	47
658	Constitutively activated G protein-coupled receptors: a novel approach to CNS drug discovery. 2002 , 1, 105-21	18
657	Antioxidant N-acetylcysteine inhibits vasoactive agents-potentiated mitogenic effect of mildly oxidized LDL on vascular smooth muscle cells. 2002 , 25, 311-5	8
656	Drug treatment for portal hypertension. 2002 , 1, 102-120	2
655	Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists. 2002 , 438, 159-70	77
654	Functional cell-based uHTS in chemical genomic drug discovery. 2002 , 20, 110-5	60
653	Emerging roles for orphan G-protein-coupled receptors in the cardiovascular system. 2002 , 1, 206-213	
652	Target validation of G-protein coupled receptors. 2002 , 7, 235-46	319

651	StructureFunction Analysis of Urotensin II and Its Use in the Construction of a LigandReceptor Working Model. 2002 , 114, 3064	2
650	Structure-function analysis of urotensin II and its use in the construction of a ligand-receptor working model. 2002 , 41, 2940-4	82
649	Urotensin II increases endothelin production by vascular smooth muscle cells in rats. 2002 , 47, 1007-1010	
648	Effect of chronic hypoxia on contents of urotensin II and its functional receptors in rat myocardium. 2002 , 16, 64-8	49
647	Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents. 2002 , 365, 141-9	87
646	Design, synthesis, conformational analysis, and biological studies of urotensin-II lactam analogues. 2002 , 10, 3731-9	44
645	Urotensin-II regulates intracellular calcium in dissociated rat spinal cord neurons. 2002 , 83, 879-84	42
644	No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans. 2002 , 54, 617-21	50
643	Urotensin II evokes potent vasoconstriction in humans in vivo. 2002 , 135, 25-7	120
642	Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey. 2002 , 136, 9-22	112
641	Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist. 2002 , 137, 449-58	40
640	A new ligand for the urotensin II receptor. 2002 , 137, 311-4	48
639	Is urotensin-II the new endothelin?. 2002 , 137, 579-88	101
638	Role of urotensin II gene in genetic susceptibility to Type 2 diabetes mellitus in Japanese subjects. 2003 , 46, 972-6	76
637	Evidence for the involvement of endothelin-1 but not urotensin-II in chronic lower limb ischaemia in man. 2003 , 25, 443-50	7
636	UROSENSIN II: BETTER THAN SOMATOSTATIN FOR PORTAL HYPERTENSION?. 2000 , 31, 1201-1202	6
635	The vasoactive peptide urotensin II stimulates spontaneous release from frog motor nerve terminals. 2003 , 138, 1580-8	23
634	The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-II receptors. 2003 , 139, 203-7	43

- 633 Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice. **2003**, 139, 464-72 52
- 632 Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta. **2003**, 140, 1155-8 84
- 631 Salusins: newly identified bioactive peptides with hemodynamic and mitogenic activities. **2003**, 9, 1166-72 141
- 630 Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain. **2003**, 310, 860-8 140
- 629 Novel human G-protein-coupled receptors. **2003**, 305, 67-71 43
- 628 Urotensin II-induced activation of extracellular signal-regulated kinase in cultured vascular smooth muscle cells: involvement of cell adhesion-mediated integrin signaling. **2003**, 72, 1049-60 42
- 627 Contraction of isolated guinea-pig ileum by urotensin II via activation of ganglionic cholinergic neurons and acetylcholine release. **2003**, 45, 1019-27 16
- 626 Expression of urotensin II and its receptor in adrenal tumors and stimulation of proliferation of cultured tumor cells by urotensin II. **2003**, 24, 301-6 58
- 625 Emerging roles for orphan G-protein-coupled receptors in the cardiovascular system. **2003**, 24, 30-5 71
- 624 Peptide and trace amine orphan receptors: prospects for new therapeutic targets. **2003**, 3, 127-34 24
- 623 Fostering orphan receptors: an indispensable role for integrative, in vivo, haemodynamic studies. **2003**, 3, 140-5 7
- 622 Discovering orphan receptor function using human in vitro pharmacology. **2003**, 3, 135-9 4
- 621 Human urotensin-II as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail?'. **2003**, 3, 159-67 94
- 620 The expression of urotensin II receptor (U2R) is up-regulated by interferon-gamma. **2003**, 23, 289-305 33
- 619 Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions. **2003**, 42, 373-9 83
- 618 Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. **2003**, 93, 246-53 184
- 617 Functional and binding characterizations of urotensin II-related peptides in human and rat urotensin II-receptor assay. **2003**, 306, 1200-9 69
- 616 Effect of human urotensin-II infusion on hemodynamics and cardiac function. **2003**, 81, 125-8 37

615	Production and characterization of monoclonal antibodies against the vasoconstrictive peptide human urotensin-II. 2003 , 22, 377-82	5
614	Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. 2003 , 285, H1576-81	93
613	Structure-activity relationships of human urotensin II and related analogues on rat aortic ring contraction. 2003 , 18, 77-88	70
612	Automation of Nonisotopic In Situ Hybridization. 2003 , 26, 181-184	3
611	Chapter 11. Urotensin-II receptor modulators. 2003 , 38, 99-110	12
610	Urotensin II is an autocrine/paracrine growth factor for the porcine renal epithelial cell line, LLCPK1. 2003 , 144, 1825-31	52
609	Central cardiovascular action of urotensin II in conscious rats. 2003 , 21, 159-65	53
608	From the Human Genome to New Drugs: The Potential of Orphan G-protein-coupled Receptors. 2003 , 95-121	1
607	Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. 2003 , 285, F792-8	80
606	Photolabelling the rat urotensin II/GPR14 receptor identifies a ligand-binding site in the fourth transmembrane domain. 2003 , 370, 829-38	43
605	Increased plasma urotensin II levels in patients with diabetes mellitus. 2003 , 104, 1-5	67
604	Urotensin II: a new player in vascular and myocardial disease?. 2003 , 104, 65-67	3
603	Increased plasma urotensin II levels in patients with diabetes mellitus. 2003 , 104, 1	120
602	Urotensin II: a new player in vascular and myocardial disease?. 2003 , 104, 65	7
601	Emerging Role of the Urotensin II System in Cardiovascular Disease. 2003 , 3, 153-158	2
600	Urotensin II causes fatal circulatory collapse in anesthetized monkeys in vivo: a "vasoconstrictor" with a unique hemodynamic profile. 2004 , 286, H830-6	33
599	Cellular distribution of GPR14 and the positive inotropic role of urotensin II in the myocardium in adult rat. 2004 , 97, 2228-35	29
598	Postgenomic characterization of G-protein-coupled receptors. 2004 , 5, 657-72	30

597	Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases. 2004 , 18, 2344-54	83
596	Expression of urocortin III/stresscopin in human heart and kidney. 2004 , 89, 1897-903	79
595	Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure. 2004 , 109, 1212-4	86
594	Vasoconstrictive effects of endothelin-1, endothelin-3, and urotensin II in isolated perfused human lungs and isolated human pulmonary arteries. 2004 , 59, 401-7	21
593	Urotensin-II-converting enzyme activity of furin and trypsin in human cells in vitro. 2004 , 310, 209-14	19
592	Stimulation of increases in intracellular calcium and prostaglandin E2 generation in Chinese hamster ovary cells expressing receptor-Galpa16 fusion proteins. 2004 , 135, 605-13	8
591	Urotensin-II is present in pancreatic extracts and inhibits insulin release in the perfused rat pancreas. 2004 , 151, 803-9	42
590	Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin System. 2004 , 311, 204-12	122
589	Regulation and function of somatostatin receptors. 2004 , 89, 1057-91	259
588	Biochemical characterization and immunohistochemical localization of urotensin II in the human brainstem and spinal cord. 2004 , 91, 110-8	37
587	Identification and pharmacological characterization of native, functional human urotensin-II receptors in rhabdomyosarcoma cell lines. 2004 , 142, 921-32	33
586	Bolus injection of human Ull in conscious rats evokes a biphasic haemodynamic response. 2004 , 143, 422-30	26
585	GPCR expression in the heart; "new" receptors in myocytes and fibroblasts. 2004 , 14, 94-9	50
584	Emerging roles of urotensin-II in cardiovascular disease. 2004 , 103, 223-43	55
583	Differential agonistic and antagonistic effects of the urotensin-II ligand SB-710411 at rodent and primate UT receptors. 2004 , 492, 113-6	20
582	Urotensin-II, a neuropeptide ligand for GPR14, induces c-fos in the rat brain. 2004 , 493, 95-8	7
581	Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors. 2004 , 498, 83-6	51
580	Central effects of native urotensin II on motor activity, ventilatory movements, and heart rate in the trout <i>Oncorhynchus mykiss</i> . 2004 , 1023, 167-74	30

579	The upregulation of endothelial nitric oxide synthase and urotensin-II is associated with pulmonary hypertension and vascular diseases in rats produced by aortocaval shunting. 2004 , 19, 81-8	38
578	Urotensin-II: a novel systemic hypertensive factor in the cat. 2004 , 369, 274-80	36
577	Cardiovascular actions of human urotensin II--considerations for hypertension. 2004 , 369, 271-3	17
576	Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. 2004 , 370, 238-50	89
575	Urotensin II stimulates plasma extravasation in mice via UT receptor activation. 2004 , 370, 347-52	17
574	Urotensin-II receptor peptide agonists. 2004 , 24, 577-88	14
573	Urotensin-II and the cardiovascular system--the importance of developing modulators. 2004 , 13, 479-87	10
572	Contractile responses of aortae from WKY and SHR to vasoconstrictors. 2004 , 26, 511-23	18
571	Orphan G protein-coupled receptors: targets for new therapeutic interventions. 2004 , 36, 204-14	44
570	Human urotensin-II enhances plasma extravasation in specific vascular districts in Wistar rats. 2004 , 82, 16-21	25
569	The identification of ligands at orphan G-protein coupled receptors. 2004 , 44, 43-66	183
568	The impact of the completed human genome sequence on the development of novel therapeutics for human disease. 2004 , 55, 1-13	41
567	Unraveling the active conformation of urotensin II. 2004 , 47, 1652-61	39
566	Biopharmaceutical Technologies and Processes in Drug Development. 2004 , 35-95	
565	Urotensin II: the old kid in town. 2004 , 15, 175-82	59
564	From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function. 2004 , 25, 76-85	132
563	Techniques: Cardiovascular pharmacology and drug discovery in the 21st century. 2004 , 25, 225-33	16
562	Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. 2004 , 25, 1767-74	104

561	Role of urotensin II in peripheral tissue as an autocrine/paracrine growth factor. 2004 , 25, 1775-81	30
560	Cardiovascular role of urotensin II: effect of chronic infusion in the rat. 2004 , 25, 1783-8	34
559	Genetic variations at urotensin II and urotensin II receptor genes and risk of type 2 diabetes mellitus in Japanese. 2004 , 25, 1803-8	42
558	Urotensin II, a novel peptide in central and peripheral cardiovascular control. 2004 , 25, 1759-66	32
557	Urotensin II in the cardiovascular system. 2004 , 25, 1795-802	36
556	Urocortins as cardiovascular peptides. 2004 , 25, 1723-31	40
555	Structure-activity relationships and structural conformation of a novel urotensin II-related peptide. 2004 , 25, 1819-30	88
554	Differential levels of "urotensin-II-like" activity determined by radio-receptor and radioimmuno-assays. 2004 , 25, 1339-47	18
553	Urotensin II and cardiovascular diseases. 2004 , 25, 1789-94	28
552	Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: association with progress of diabetic nephropathy. 2004 , 25, 1809-14	85
551	Urotensin II-related peptide, the endogenous ligand for the urotensin II receptor in the rat brain. 2004 , 25, 1815-8	19
550	Urotensin-II activates L-arginine/nitric oxide pathway in isolated rat aortic adventitia. 2004 , 25, 1977-84	17
549	The relationship between urotensin II plasma immunoreactivity and left ventricular filling pressures in coronary artery disease. 2004 , 121, 129-36	56
548	Intracerebroventricular administration of urotensin II promotes angiogenic-like behaviors in rodents. 2004 , 358, 99-102	36
547	Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy. 2004 , 94, 93-7	68
546	[What progress can be expected in the management of hypertension? Forecast from 1974 to 2034]. 2004 , 33, 721-32	1
545	Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. 2004 , 176, 117-23	116
544	Plasma concentration of urotensin II is raised in hypertension. 2004 , 22, 1341-4	124

543	Human urotensin II modulates collagen synthesis and the expression of MMP-1 in human endothelial cells. 2004 , 44, 577-81	40
542	Role of ERK and Rho kinase pathways in central pressor action of urotensin II. 2004 , 22, 983-8	12
541	Translational medicine in fish-derived peptides: from fish endocrinology to human physiology and diseases. 2004 , 51, 1-17	22
540	Mechanism of human urotensin II-induced contraction in rat aorta. 2004 , 94, 376-83	32
539	Involvement of a cytoplasmic-tail serine cluster in urotensin II receptor internalization. 2005 , 385, 115-23	17
538	Isochromanone-based urotensin-II receptor agonists. 2005 , 13, 3057-68	37
537	Aminoalkoxybenzyl pyrrolidines as novel human urotensin-II receptor antagonists. 2005 , 15, 3229-32	26
536	Urotensin II: ancient hormone with new functions in vertebrate body fluid regulation. 2005 , 1040, 66-73	25
535	Time-course effects of centrally administered native urotensin-II on motor and cardioventilatory activity in trout. 2005 , 1040, 371-4	4
534	Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375. 2005 , 145, 620-35	48
533	From heart to mind. The urotensin II system and its evolving neurophysiological role. 2005 , 272, 5694-702	17
532	Inhibitory effects of putative peptidic urotensin-II receptor antagonists on urotensin-II-induced contraction of cat isolated respiratory smooth muscle. 2005 , 516, 276-81	6
531	Role of prostaglandins in urotensin II-induced vasodilatation in the coronary arteries of aged rats. 2005 , 523, 119-26	22
530	Cloning and pharmacological characterization of the cat urotensin-II receptor (UT). 2005 , 69, 1069-79	18
529	Urotensin II acts as a modulator of mesopontine cholinergic neurons. 2005 , 1059, 139-48	18
528	Urotensin II and the Circulatory System. 2005 , 7, 9-13	1
527	Behavioral effects of urotensin-II centrally administered in mice. 2005 , 183, 103-17	46
526	Urotensin-II levels in children with minimal change nephrotic syndrome. 2005 , 20, 42-5	16

525	Expression pattern of the orphan receptor LGR4/GPR48 gene in the mouse. 2005 , 124, 35-50	65
524	Urotensin II: its function in health and its role in disease. 2005 , 19, 65-75	68
523	Structure-activity relationship study on human urotensin II. 2005 , 11, 85-90	32
522	Discovery of novel regulatory peptides by reverse pharmacology: spotlight on chemerin and the RF-amide peptides metastin and QRFP. 2005 , 6, 265-78	19
521	Urotensin II: a vascular mediator in health and disease. 2005 , 3, 159-68	9
520	Urotensin II in patients with chronic heart failure. 2005 , 7, 475-8	14
519	The G Protein-Coupled Receptors Handbook. 2005 ,	3
518	Arrestin-independent internalization and recycling of the urotensin receptor contribute to long-lasting urotensin II-mediated vasoconstriction. 2005 , 97, 707-15	36
517	G-protein-coupled receptor deorphanizations. 2005 , 65, 179-209	6
516	Urotensin II modulates rapid eye movement sleep through activation of brainstem cholinergic neurons. 2005 , 25, 5465-74	62
515	Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages. 2005 , 46, 738-44	93
514	The multifunctional fish gill: dominant site of gas exchange, osmoregulation, acid-base regulation, and excretion of nitrogenous waste. 2005 , 85, 97-177	1763
513	Metallacyclopeptides: artificial analogues of naturally occurring peptides. 2005 , 34, 496-506	42
512	Urotensin-II receptor ligands. From agonist to antagonist activity. 2005 , 48, 7290-7	22
511	Architecture of the human urotensin II receptor: comparison of the binding domains of peptide and non-peptide urotensin II agonists. 2005 , 48, 2480-92	30
510	A novel hypothalamic neuroendocrine peptide: URP (urotensin-II-related peptide)?. 2005 , 328, 724-31	9
509	Involvement of cyclooxygenase-dependent pathway in contraction of isolated ileum by urotensin II. 2005 , 26, 323-9	9
508	Characterization of functional urotensin II receptors in human skeletal muscle myoblasts: comparison with angiotensin II receptors. 2005 , 26, 683-90	31

507	Cardiac actions of central but not peripheral urotensin II are prevented by beta-adrenoceptor blockade. 2005 , 26, 1248-56	22
506	Urotensin II-induced hypotensive responses in Wistar-Kyoto (Wky) and spontaneously hypertensive (Shr) rats. 2005 , 26, 1468-74	21
505	Development and pharmacological characterization of "caged" urotensin II analogs. 2005 , 26, 1475-80	9
504	Urotensin II: evidence for cardiac, hepatic and renal production. 2005 , 26, 2211-4	45
503	Expression of urotensin-II in human coronary atherosclerosis. 2005 , 26, 2464-72	70
502	A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker. 2005 , 39, 785-91	55
501	Regulation of vascular reactivity by established and emerging GPCRs. 2005 , 26, 448-54	66
500	Androgenic down-regulation of urotensin II precursor, urotensin II-related peptide precursor and androgen receptor mRNA in the mouse spinal cord. 2005 , 132, 689-96	36
499	Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension. 2005 , 18, 1195-9	45
498	Over one hundred peptide-activated G protein-coupled receptors recognize ligands with turn structure. 2005 , 105, 793-826	201
497	Bioinformatics and Drug Discovery. 2006 ,	1
496	Cardiovascular Biomarkers. 2006 ,	2
495	Proliferation and anti-apoptotic effects of human urotensin II on human endothelial cells. 2006 , 188, 260-4	45
494	Human urotensin-II potentiates the mitogenic effect of mildly oxidized low-density lipoprotein on vascular smooth muscle cells: comparison with other vasoactive agents and hydrogen peroxide. 2006 , 29, 821-31	26
493	Cellular and molecular biology of orphan G protein-coupled receptors. 2006 , 252, 163-218	42
492	Characterization of urotensin-II receptor structural domains involved in the recognition of U-II, URP, and urantide. 2006 , 45, 5993-6002	17
491	Design and synthesis of potent cystine-free cyclic hexapeptide agonists at the human urotensin receptor. 2006 , 8, 1799-802	12
490	Structure-activity relationships of a novel series of urotensin II analogues: identification of a urotensin II antagonist. 2006 , 49, 7234-8	27

489	Urotensin II and biomarkers of endothelial activation and atherosclerosis in end-stage renal disease. 2006 , 19, 505-10	18
488	Urotensin and cardiovascular risk among patients with end-stage renal disease: fact or fiction?. 2006 , 19, 511-2	1
487	Effects of hydrogen sulfide on hypoxic pulmonary vascular structural remodeling. 2006 , 78, 1299-309	63
486	Urotensin-II is a nitric oxide-dependent vasodilator in the pial arteries of the newborn pig. 2006 , 78, 2763-6	14
485	Urotensin-II expression in the mouse spinal cord. 2006 , 31, 146-54	15
484	Urotensin-II levels in acute coronary syndromes. 2006 , 108, 31-5	30
483	Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation. 2006 , 41, 285-95	54
482	Vascular contractile effect of urotensin II in young and aged rats: influence of aging and contribution of endothelial nitric oxide. 2006 , 27, 80-6	10
481	Alteration of vascular urotensin II receptor in mice with apolipoprotein E gene knockout. 2006 , 27, 858-63	24
480	Identification and characterization of binding sites for human urotensin-II in Sprague-Dawley rat renal medulla using quantitative receptor autoradiography. 2006 , 27, 1532-7	14
479	Circulating urotensin II levels in moderate to severe congestive heart failure: its relations with myocardial function and well established neurohormonal markers. 2006 , 27, 1527-31	49
478	Haplotypes in the urotensin II gene and urotensin II receptor gene are associated with insulin resistance and impaired glucose tolerance. 2006 , 27, 1659-67	42
477	Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease. 2006 , 27, 2919-26	51
476	Cardiovascular effects of native and non-native urotensin II and urotensin II-related peptide on rat and salmon hearts. 2006 , 27, 3261-8	23
475	Urotensin and Its Related Peptides. 2006 , 1209-1213	
474	Urotensin II and Urotensin II Related Peptide. 2006 , 795-803	1
473	Urotensin-II and UIR-receptor expression and function in the rat adrenal cortex. 2006 , 17, 1111	1
472	Photolabeling with N-Terminal Urotensin II Photoprobes Identifies Methionine 288 of Rat Urotensin Receptor as a Contact Point. 2006 , 455-456	

471	Urotensin-II and its receptor (UT-R) are expressed in rat brain endothelial cells, and urotensin-II via UT-R stimulates angiogenesis in vivo and in vitro. 2006 , 18, 1107	3
470	Renal effects of human urotensin-II in rats with experimental congestive heart failure. 2006 , 21, 1205-11	18
469	Non-peptidic urotensin-II receptor modulators. 2006 , 16, 467-479	11
468	Biochemical and functional characterization of high-affinity urotensin II receptors in rat cortical astrocytes. 2006 , 99, 582-95	47
467	In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5,DTrp7,Dab8]urotensin II(4-11) (UFP-803). 2006 , 147, 92-100	29
466	Regional heterogeneity in the haemodynamic responses to urotensin II infusion in relation to UT receptor localisation. 2006 , 147, 612-21	18
465	The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems. 2006 , 148, 173-90	29
464	The role of urotensin II in cardiovascular and renal physiology and diseases. 2006 , 148, 884-901	54
463	Urotensin II is an inverse predictor of incident cardiovascular events in end-stage renal disease. 2006 , 69, 1253-8	29
462	Urotensin II and renal function in the rat. 2006 , 69, 1360-8	56
461	Renal and vascular actions of urotensin II. 2006 , 70, 624-9	33
460	Human urotensin II as a link between hypertension and coronary artery disease. 2006 , 29, 375-87	56
459	Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity. 2006 , 373, 148-57	19
458	Enhancement of vascular smooth muscle cell migration by urotensin II. 2006 , 373, 381-6	22
457	The in vivo effects of human urotensin II in the rabbit and rat pulmonary circulation: effects of experimental pulmonary hypertension. 2006 , 537, 135-42	2
456	Localization of the urotensin II receptor in the rat central nervous system. 2006 , 495, 21-36	58
455	New strategies in drug discovery. 2006 , 316, 1-11	5
454	Molecular characterization and expression of urotensin II and its receptor in the flounder (<i>Platichthys flesus</i>): a hormone system supporting body fluid homeostasis in euryhaline fish. 2006 , 147, 3692-708	53

- 453 Urotensin II is raised in children with congenital heart disease. **2006**, 92, 983-4 17
- 452 Relationship Between Hypertension and Atherosclerosis: From a Viewpoint of the Most Potent Vasoconstrictor Human Urotensin II. **2006**, 2, 237-246 2
- 451 Association of ACE, ACE2 and UTS2 polymorphisms with essential hypertension in Han and Dongxiang populations from north-western China. **2006**, 34, 272-83 64
- 450 The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. **2006**, 316, 1115-21 71
- 449 G-protein-coupled receptor microarrays for multiplexed compound screening. **2006**, 11, 435-8 16
- 448 The etiology of hypertension in the metabolic syndrome part three: the regulation and dysregulation of blood pressure. **2006**, 4, 321-48 6
- 447 Comparative genomics provides evidence for close evolutionary relationships between the urotensin II and somatostatin gene families. **2006**, 103, 2237-42 75
- 446 Urotensin II is a new chemotactic factor for UT receptor-expressing monocytes. **2007**, 179, 901-9 64
- 445 Nonclassic endogenous novel [corrected] regulators of angiogenesis. **2007**, 59, 185-205 148
- 444 Urotensin-II immunoreactivity in children with chronic glomerulonephritis. **2007**, 29, 573-8 22
- 443 Evaluation of no-wash calcium assay kits: enabling tools for calcium mobilization. **2007**, 12, 705-14 14
- 442 Urotensin II: from osmoregulation in fish to cardiovascular regulation in man. **2007**, 98, 557-9 4
- 441 Ligands and signaling of the G-protein-coupled receptor GPR14, expressed in human kidney cells. **2007**, 20, 181-92 10
- 440 Photolabelling the urotensin II receptor reveals distinct agonist- and partial-agonist-binding sites. **2007**, 402, 51-61 15
- 439 Orphan seven transmembrane receptor screening. **2006**, 105-43 6
- 438 A review of the genetics of essential hypertension. **2007**, 22, 176-84 84
- 437 The involvement of transforming growth factor-beta1 secretion in urotensin II-induced collagen synthesis in neonatal cardiac fibroblasts. **2007**, 140, 88-93 27
- 436 QSAR modeling of GPCR ligands: methodologies and examples of applications. **2006**, 49-73 10

435	Nonpeptidic ligands for peptide-activated G protein-coupled receptors. 2007 , 107, 2960-3041	84
434	Emerging concepts of guanine nucleotide-binding protein-coupled receptor (GPCR) function and implications for high throughput screening. 2007 , 5, 425-51	81
433	Ligand screening system using fusion proteins of G protein-coupled receptors with G protein alpha subunits. 2007 , 51, 140-64	12
432	Urotensin II is raised in acute myocardial infarction and low levels predict risk of adverse clinical outcome in humans. 2007 , 117, 323-8	49
431	Cardiovascular Activity. 2007 , 47-391	
430	Urotensin II inhibits carotid sinus baroreflex in anesthetized male rats. 2007 , 28, 216-20	2
429	Definition of new pharmacophores for nonpeptide antagonists of human urotensin-II. Comparison with the 3D-structure of human urotensin-II and URP. 2007 , 47, 602-12	16
428	Other Peptide and Related Systems including Substance P, Calcitonin Gene-Related Peptide, and Serotonin. 2007 , 363-375	
427	Urotensin-II in the lung: A matter for vascular remodelling and pulmonary hypertension?. 2007 , 98, 952-962	10
426	Role of PKC in the novel synergistic action of urotensin II and angiotensin II and in urotensin II-induced vasoconstriction. 2007 , 292, H348-59	30
425	Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats. 2008 , 47, 1264-76	69
424	Phenylpiperidine-benzoxazinones as urotensin-II receptor antagonists: synthesis, SAR, and in vivo assessment. 2007 , 17, 6489-92	17
423	Total synthesis of human urotension-II by microwave-assisted solid phase method. 2007 , 18, 902-904	7
422	Urotensin-II induces ear flushing in rats. 2007 , 150, 415-23	7
421	Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension. 2007 , 27, 1232-9	22
420	Urotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol. 2007 , 28, 36-43	42
419	A 'reverse' phylogenetic approach for identification of novel osmoregulatory and cardiovascular hormones in vertebrates. 2007 , 28, 143-60	38
418	Fish caudal neurosecretory system: a model for the study of neuroendocrine secretion. 2007 , 153, 243-50	28

417	Seasonal changes in peptide, receptor and ion channel mRNA expression in the caudal neurosecretory system of the European flounder (<i>Platichthys flesus</i>). 2007 , 153, 262-72	21
416	Urotensin II acutely increases myocardial length and distensibility: potential implications for diastolic function and ventricular remodeling. 2007 , 376, 107-15	12
415	Does cigarette smoking increase plasma urotensin II concentrations?. 2007 , 63, 253-7	9
414	Role of urotensin II and its receptor in health and disease. 2007 , 21, 378-89	31
413	Therapeutic potential of blockade of the urotensin II system in systemic hypertension. 2007 , 9, 53-8	16
412	Three-dimensional model of the human urotensin-II receptor: docking of human urotensin-II and nonpeptide antagonists in the binding site and comparison with an antagonist pharmacophore model. 2008 , 73, 173-84	9
411	Transcriptional profiling of the megabladder mouse: a unique model of bladder dysmorphogenesis. 2008 , 237, 170-86	11
410	2-Aminomethyl piperidines as novel urotensin-II receptor antagonists. 2008 , 18, 2860-4	13
409	Development of potent and selective small-molecule human Urotensin-II antagonists. 2008 , 18, 3500-3	9
408	Urotensin-II receptor antagonists: synthesis and SAR of N-cyclic azaalkyl benzamides. 2008 , 18, 3950-4	12
407	Aminomethylpiperazines as selective urotensin antagonists. 2008 , 18, 4470-3	13
406	N-alkyl-5H-pyrido[4,3-b]indol-1-amines and derivatives as novel urotensin-II receptor antagonists. 2008 , 18, 4936-9	14
405	Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles. 2008 , 18, 3716-9	7
404	Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues. 2008 , 155, 374-86	21
403	Characterization of urotensin II, distribution of urotensin II, urotensin II-related peptide and UT receptor mRNAs in mouse: evidence of urotensin II at the neuromuscular junction. 2008 , 107, 361-74	32
402	Human urotensin II induces tissue factor and cellular adhesion molecules expression in human coronary endothelial cells: an emerging role for urotensin II in cardiovascular disease. 2008 , 6, 726-36	32
401	Effect of urotensin II on skin microvessel tone in diabetic patients without heart failure or essential hypertension. 2008 , 35, 1147-50	12
400	Urotensin II: lessons from comparative studies for general endocrinology. 2008 , 157, 14-20	12

399	Role of urotensin II in atherosclerotic cardiovascular diseases. 2008 , 9, 166-78	23
398	Involvement of reactive oxygen species in urotensin II-induced proliferation of cardiac fibroblasts. 2008 , 593, 24-9	28
397	Elevated expression of urotensin II and its receptor in diabetic cardiomyopathy. 2008 , 22, 137-43	14
396	Therapeutic targets in hypertension: is there a place for antagonists of the most potent vasoconstrictors?. 2008 , 12, 327-39	14
395	Effect of central urotensin II on heart rate, blood pressure and brain Fos immunoreactivity in conscious rats. 2008 , 155, 241-9	11
394	Automated synthesis of the generic peptide labelling agent N-succinimidyl 4-[(18)F]fluorobenzoate and application to (18)F-label the vasoactive transmitter urotensin-II as a ligand for positron emission tomography. 2008 , 35, 725-31	24
393	Urotensin II is an autocrine/paracrine growth factor for aortic adventitia of rat. 2008 , 151, 88-94	8
392	Liberation of urotensin II from the teleost urophysis: an historical overview. 2008 , 29, 651-7	18
391	The role of urotensin II in the metabolic syndrome. 2008 , 29, 859-67	45
390	Another ligand fishing for G protein-coupled receptor 14. Discovery of urotensin II-related peptide in the rat brain. 2008 , 29, 809-12	26
389	Central and peripheral cardiovascular, ventilatory, and motor effects of trout urotensin-II in the trout. 2008 , 29, 830-7	21
388	Immunolocalization of urotensin II and its receptor in human adrenal tumors and attached non-neoplastic adrenal tissues. 2008 , 29, 873-80	27
387	Structure-activity relationship study of position 4 in the urotensin-II receptor ligand U-II(4-11). 2008 , 29, 674-9	2
386	Urotensin II and urotensin II-related peptide (URP) in cardiac ischemia-reperfusion injury. 2008 , 29, 770-7	39
385	Structure-activity relationships of urotensin II and URP. 2008 , 29, 658-73	49
384	Increased circulating urotensin II in cirrhosis: potential implications in liver disease. 2008 , 29, 868-72	12
383	Immunocytochemical localization of the urotensin-II receptor, UT, to rat and human tissues: relevance to function. 2008 , 29, 735-42	29
382	Urotensin II and atherosclerosis. 2008 , 29, 778-82	30

381	Evidence for endogenous urotensin-II as an inhibitor of insulin secretion. Study in the perfused rat pancreas. 2008 , 29, 852-8	16
380	Cardiorenovascular effects of urotensin II and the relevance of the UT receptor. 2008 , 29, 743-63	34
379	Urotensin-II and cardiovascular remodeling. 2008 , 29, 764-9	34
378	Nonpeptide Urotensin-II receptor agonists and antagonists: review and structure-activity relationships. 2008 , 29, 680-90	28
377	[Orn5]URP acts as a pure antagonist of urotensinergic receptors in rat cortical astrocytes. 2008 , 29, 813-9	8
376	Biological properties and functional determinants of the urotensin II receptor. 2008 , 29, 691-9	42
375	Urotensin II and urotensin II-related peptide activate somatostatin receptor subtypes 2 and 5. 2008 , 29, 711-20	27
374	Behavioral actions of urotensin-II. 2008 , 29, 838-44	22
373	Increased gene expression of urotensin II-related peptide in the hearts of rats with congestive heart failure. 2008 , 29, 801-8	22
372	State-dependent calcium mobilization by urotensin-II in cultured human endothelial cells. 2008 , 29, 721-6	13
371	Biologically active peptides urotensin II (UII) and urotensin II-related peptide (URP), and to their cognate receptor (UT). Editorial. 2008 , 29, 647-8	2
370	Effect of GABA A receptor activation on UT-coupled signaling pathways in rat cortical astrocytes. 2008 , 29, 727-34	8
369	Neuropeptide interactions and REM sleep: a role for Urotensin II?. 2008 , 29, 845-51	16
368	Hemodynamic-independent anti-natriuretic effect of urotensin II in spontaneously hypertensive rats. 2008 , 29, 783-94	8
367	Solution structure of urotensin-II receptor extracellular loop III and characterization of its interaction with urotensin-II. 2008 , 29, 700-10	12
366	PPAR-gamma expression in animals subjected to volume overload and chronic Urotensin II administration. 2008 , 29, 795-800	4
365	Effects of urotensin-II on cerebral blood flow and ischemia in anesthetized rats. 2008 , 210, 577-84	10
364	Murine and rat cavernosal responses to endothelin-1 and urotensin-II Vasoactive Peptide Symposium. 2008 , 2, 439-447	5

363	New insight into the molecular evolution of the somatostatin family. 2008 , 286, 5-17	62
362	Urotensin II in chronic liver disease: in vivo effect on vascular tone. 2008 , 43, 103-9	6
361	Skin vasodilator effect of exogenous urotensin-II in hypertensives not exposed to antihypertensive medication. 2008 , 17, 18-25	4
360	Ribosomal synthesis of peptidase-resistant peptides closed by a nonreducible inter-side-chain bond. 2008 , 3, 241-9	71
359	Ribosomal synthesis of nonstandard peptides. 2008 , 86, 92-9	23
358	Mutational analysis of the conserved Asp2.50 and ERY motif reveals signaling bias of the urotensin II receptor. 2008 , 74, 552-61	21
357	Diabetes-induced upregulation of urotensin II and its receptor plays an important role in TGF-beta1-mediated renal fibrosis and dysfunction. 2008 , 295, E1234-42	35
356	Enhanced renal sensitivity of the spontaneously hypertensive rat to urotensin II. 2008 , 295, F1239-47	11
355	Renal haemodynamic and tubular actions of urotensin II in the rat. 2008 , 198, 617-24	17
354	Urotensin II and cardiomyopathy in end-stage renal disease. 2008 , 51, 326-33	17
353	Urotensin II is an inverse predictor of death and fatal cardiovascular events in chronic kidney disease. 2008 , 73, 95-101	17
352	Increased plasma urotensin-II levels are associated with diabetic retinopathy and carotid atherosclerosis in Type 2 diabetes. 2008 , 115, 327-34	28
351	Urotensin II induces phenotypic differentiation, migration, and collagen synthesis of adventitial fibroblasts from rat aorta. 2008 , 26, 1119-26	36
350	Chronic urotensin II infusion enhances macrophage foam cell formation and atherosclerosis in apolipoprotein E-knockout mice. 2008 , 26, 1955-65	26
349	Urotensin II: a new pharmacologic target in the treatment of cardiovascular disease. 2008 , 16, 142-53	27
348	Urotensin II: a cardiovascular and renal update. 2008 , 17, 199-204	22
347	Urotensin II in cardiovascular regulation. 2008 , 4, 775-85	26
346	Comparative understanding of UTS2 and UTS2R genes for their involvement in type 2 diabetes mellitus. 2008 , 4, 96-102	18

345	Molecular subsets in the gene expression signatures of scleroderma skin. 2008 , 3, e2696	276
344	Increased plasma urotensin-II and carotid atherosclerosis are associated with vascular dementia. 2009 , 16, 179-87	25
343	Pharmacokinetics and pharmacodynamics of the urotensin-II receptor antagonist palosuran in healthy male subjects. 2009 , 49, 1168-75	13
342	Direct inotropic effects of exogenous and endogenous urotensin-II: divergent actions in failing and nonfailing human myocardium. 2009 , 2, 39-46	16
341	Human urotensin II promotes hypertension and atherosclerotic cardiovascular diseases. 2009 , 16, 550-63	39
340	Urotensin II modulates hepatic fibrosis and portal hemodynamic alterations in rats. 2009 , 297, G762-7	16
339	Expression and functional role of urotensin-II and its receptor in the adrenal cortex and medulla: novel insights for the pathophysiology of primary aldosteronism. 2009 , 94, 684-90	23
338	Prolonged RXFP1 and RXFP2 signaling can be explained by poor internalization and a lack of beta-arrestin recruitment. 2009 , 296, C1058-66	38
337	Urotensin II immunoreactivity in the human circulation: evidence for widespread tissue release. 2009 , 55, 2040-8	15
336	Urotensin II receptor knockout mice on an ApoE knockout background fed a high-fat diet exhibit an enhanced hyperlipidemic and atherosclerotic phenotype. 2009 , 105, 686-95, 19 p following 695	12
335	Chapter 8 The Neuroendocrine Regulation of Fluid Intake and Fluid Balance. 2009 , 365-419	14
334	Urotensin I-CRF-Urocortins: a mermaid's tail. 2009 , 164, 7-14	8
333	Identification of transmembrane domain 6 & 7 residues that contribute to the binding pocket of the urotensin II receptor. 2009 , 77, 1374-82	10
332	Desensitisation of native and recombinant human urotensin-II receptors. 2009 , 380, 451-7	5
331	The effects of urotensin II and urantide on forearm blood flow and systemic haemodynamics in humans. 2009 , 68, 518-23	8
330	Magnolol depresses urotensin-II-induced cell proliferation in rat cardiac fibroblasts. 2009 , 36, 711-6	15
329	Norfloxacin treatment for clinically significant portal hypertension: results of a randomised double-blind placebo-controlled crossover trial. 2009 , 29, 427-33	27
328	Novel and potent small-molecule urotensin II receptor agonists. 2009 , 17, 4657-65	4

327	Identification of new agonists of urotensin-II from a cyclic peptide library. 2009 , 17, 6742-7	3
326	New insight into the binding mode of peptide ligands at Urotensin-II receptor: structure-activity relationships study on P5U and urantide. 2009 , 52, 3927-40	21
325	Nonpeptide urotensin-II receptor antagonists: a new ligand class based on piperazino-phthalimide and piperazino-isoindolinone subunits. 2009 , 52, 7432-45	59
324	Elevated expression of urotensin II and its receptor in great artery of type 2 diabetes and its significance. 2009 , 63, 734-41	8
323	Characterization of the insulinostatic effect of urotensin II: a study in the perfused rat pancreas. 2009 , 153, 37-42	8
322	Elevated expression of urotensin II and its receptor in skeletal muscle of diabetic mouse. 2009 , 154, 85-90	14
321	Pro-angiogenic activity of Urotensin-II on different human vascular endothelial cell populations. 2009 , 157, 64-71	16
320	Increased expression of urotensin II-related peptide and its receptor in kidney with hypertension or renal failure. 2009 , 30, 400-8	28
319	Structure-activity relationship study on Tyr9 of urotensin-II(4-11): identification of a partial agonist of the UT receptor. 2009 , 30, 1130-6	8
318	Increased expression of urotensin II, urotensin II-related peptide and urotensin II receptor mRNAs in the cardiovascular organs of hypertensive rats: comparison with endothelin-1. 2009 , 30, 1124-9	31
317	The renin-angiotensin system, adrenomedullins and urotensin II in the kidney: possible renoprotection via the kidney peptide systems. 2009 , 30, 1575-85	24
316	Neural and Humoral Control of the Airways. 2009 , 381-397	
315	Targeted overexpression of the human urotensin receptor transgene in smooth muscle cells: effect of UT antagonism in ApoE knockout mice fed with Western diet. 2009 , 204, 395-404	18
314	Urotensin II-induced endothelin-1 expression and cell proliferation via epidermal growth factor receptor transactivation in rat aortic smooth muscle cells. 2009 , 206, 86-94	23
313	Plasma urotensin II as a marker for severity of rheumatic valve disease. 2009 , 218, 57-62	8
312	Deprotection of the indole (N(ind))-formyl (For) group on tryptophan employing a new reagent, N,N'-dimethylethyldiamine (DMEDA) in an aqueous solution. 2009 , 57, 211-3	4
311	Urotensin II induces migration of endothelial progenitor cells via activation of the RhoA/Rho kinase pathway. 2009 , 219, 283-8	20
310	The urotension II antagonist SB-710411 arrests fibrosis in CCL4 cirrhotic rats. 2009 , 2, 953-61	7

- 309 Endogenous Vasoactive Peptides. **2010**, 515-566
- 308 Expression of urotensin II and its receptor in human lung adenocarcinoma A549 cells and the effect of urotensin II on lung adenocarcinoma growth in vitro and in vivo. **2010**, 24, 1179-84 16
- 307 The vasoactive peptides urotensin II and urotensin II-related peptide regulate astrocyte activity through common and distinct mechanisms: involvement in cell proliferation. **2010**, 428, 113-24 47
- 306 The Role of Translational Medicine and Predictive Biomarkers in the Development of Novel, Innovative Treatments for the Management of Chronic Heart Failure: A Pharmaceutical Industry Perspective. **2010**, 477-514
- 305 Update 1 of: Over one hundred peptide-activated G protein-coupled receptors recognize ligands with turn structure. **2010**, 110, PR1-41 58
- 304 A rat brain atlas of urotensin-II receptor expression and a review of central urotensin-II effects. **2010**, 382, 1-31 10
- 303 Expression of urotensin II and its receptor in human liver cirrhosis and fulminant hepatic failure. **2010**, 55, 1458-64 12
- 302 Human urotensin II in internal mammary and radial arteries of patients undergoing coronary surgery. **2010**, 52, 70-6 13
- 301 Urotensin II: a novel target in human corpus cavernosum. **2010**, 7, 1778-86 11
- 300 Raised plasma urotensin II in type 2 diabetes patients is associated with the metabolic syndrome phenotype. **2010**, 12, 653-60 20
- 299 Prediction of the three-dimensional structure for the rat urotensin II receptor, and comparison of the antagonist binding sites and binding selectivity between human and rat receptors from atomistic simulations. **2010**, 5, 1594-608 18
- 298 Optimization of isochromanone based urotensin II receptor agonists. **2010**, 18, 4844-54 10
- 297 GSK1562590, a slowly dissociating urotensin-II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivo. **2010**, 161, 207-28 23
- 296 Effect of urotensin II on PC12 rat pheochromocytoma cells. **2010**, 22, 83-91 8
- 295 Effects of exogenous urotensin II on vascular remodelling after balloon injury. **2010**, 37, 477-81 6
- 294 Urotensin-II receptor antagonism does not improve renal haemodynamics or function in rats with endotoxin-induced acute kidney injury. **2010**, 37, 1170-5 2
- 293 Urotensin II-induced signaling involved in proliferation of vascular smooth muscle cells. **2010**, 6, 723-34 17
- 292 Increased expression of urotensin II and GPR14 in patients with cirrhosis and portal hypertension. **2010**, 25, 845-51 14

291	Role of urotensin II in health and disease. 2010 , 298, R1156-72	97
290	Urotensin II, from fish to human. 2010 , 1200, 53-66	80
289	Upregulation of urotensin II receptor in preeclampsia causes in vitro placental release of soluble vascular endothelial growth factor receptor 1 in hypoxia. 2010 , 56, 172-8	19
288	Urotensin II receptor antagonist attenuates monocrotaline-induced cardiac hypertrophy in rats. 2010 , 299, H1782-9	13
287	Chronic urotensin-II infusion induces diastolic dysfunction and enhances collagen production in rats. 2010 , 298, H608-13	27
286	Urotensin-II contributes to pulmonary vasoconstriction in a perinatal model of persistent pulmonary hypertension of the newborn secondary to meconium aspiration syndrome. 2010 , 67, 150-7	14
285	Urotensin II stimulates high frequency-induced ANP secretion via PLC-PI 3K-PKC pathway. 2010 , 31, 164-9	5
284	Urotensin-II as an angiogenic factor. 2010 , 31, 1219-24	28
283	Urotensin II induction of adult cardiomyocytes hypertrophy involves the Akt/GSK-3beta signaling pathway. 2010 , 31, 1326-33	28
282	Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis. 2010 , 31, 1511-6	10
281	Chronic urotensin II receptor antagonist treatment does not alter hypertrophy or fibrosis in a rat model of pressure-overload hypertrophy. 2010 , 31, 1523-30	16
280	Urotensin II alters vascular reactivity in animals subjected to volume overload. 2010 , 31, 2075-82	2
279	Urotensin II receptor and acetylcholine release from mouse cervical spinal cord nerve terminals. 2010 , 170, 67-77	12
278	The pro-angiogenic activity of urotensin-II on human vascular endothelial cells involves ERK1/2 and PI3K signaling pathways. 2010 , 162, 26-32	16
277	Neurokinin B and urotensin II levels in pre-eclampsia. 2010 , 23, 869-73	4
276	Development of filtration-based time-resolved fluorescence assay for the high-throughput screening of urotensin II receptor antagonist. 2011 , 9, 514-21	6
275	Urotensin-2 promotes collagen synthesis via ERK1/2-dependent and ERK1/2-independent TGF- β in neonatal cardiac fibroblasts. 2011 , 35, 93-8	19
274	The Endothelium, Part II: EDHF-Mediated Responses "The Classical Pathway". 2011 , 3, 1-306	2

- 273 Urotensin II differentially regulates macrophage and hepatic cholesterol homeostasis. **2011**, 32, 956-63 16
- 272 Osteopontin is involved in urotensin II-induced migration of rat aortic adventitial fibroblasts. **2011**, 32, 2452-8 5
- 271 Urantide alleviates monocrotaline induced pulmonary arterial hypertension in Wistar rats. **2011**, 24, 386-93 14
- 270 Potential Clinical Implications of the Urotensin II Receptor Antagonists. **2011**, 2, 38 30
- 269 Urotensin II levels are an important marker for the severity of portal hypertension in children. **2011**, 53, 88-92 6
- 268 Urotensin-II 143 G/A polymorphism is not associated with the risk of preeclampsia in Korean women. **2011**, 66, 423-7 1
- 267 Urotensin-II-stimulated expression of pro-angiogenic factors in human vascular endothelial cells. **2011**, 172, 16-22 20
- 266 Management of the no-reflow phenomenon. **2011**, 132, 72-85 21
- 265 Influence of Ca²⁺ and pH on the folding of the prourotesin II precursor. **2011**, 585, 1910-4 2
- 264 The interaction between human urotensin II and vasodilator agents in human internal mammary artery with possible clinical implications. **2011**, 92, 610-6 8
- 263 The Endothelium, Part I: Multiple Functions of the Endothelial Cells -- Focus on Endothelium-Derived Vasoactive Mediators. **2011**, 3, 1-306 38
- 262 EGFR trans-activation by urotensin II receptor is mediated by β arrestin recruitment and confers cardioprotection in pressure overload-induced cardiac hypertrophy. **2011**, 106, 577-89 50
- 261 Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells. **2011**, 112, 341-53 27
- 260 Renal impairment, hypertension and plasma urotensin II. **2011**, 26, 609-14 15
- 259 Occurrence of two distinct urotensin II-related peptides in zebrafish provides new insight into the evolutionary history of the urotensin II gene family. **2011**, 152, 2330-41 27
- 258 . **2011**, 15 15
- 257 A closer look at the role of urotensin II in the metabolic syndrome. **2012**, 3, 165 20
- 256 Urotensin-II: More Than a Mediator for Kidney. **2012**, 2012, 249790 7

255	Novel pathways and therapies in experimental diabetic atherosclerosis. 2012 , 10, 323-35	9
254	The HIF1 target gene NOX2 promotes angiogenesis through urotensin-II. 2012 , 125, 956-64	52
253	Genetic and pharmacological manipulation of urotensin II ameliorate the metabolic and atherosclerosis sequelae in mice. 2012 , 32, 1809-16	37
252	Urotensin-II signaling mechanism in rat coronary artery: role of STIM1 and Orai1-dependent store operated calcium influx in vasoconstriction. 2012 , 32, 1325-32	33
251	Urotensin II promotes the proliferation of endothelial progenitor cells through p38 and p44/42 MAPK activation. 2012 , 6, 197-200	10
250	Urotensin II contributes to the formation of lung adenocarcinoma inflammatory microenvironment through the NF- κ B pathway in tumor-bearing nude mice. 2012 , 4, 1259-1263	15
249	Evaluation of the effects of urotensin II and soluble epoxide hydrolase inhibitor on skin microvessel tone in healthy controls and heart failure patients. 2012 , 30, 295-300	16
248	Association between Thr21Met and Ser89Asn polymorphisms of the urotensin-II (UTS2) gene, diabetes mellitus, and diabetic retinopathy. 2012 , 37, 921-9	16
247	. 2012 ,	
246	Effects of urotensin II on functional activity of late endothelial progenitor cells. 2012 , 33, 87-91	5
245	Biochemical and pharmacological characterization of nuclear urotensin-II binding sites in rat heart. 2012 , 166, 243-57	28
244	Molecular Cloning of Drug Targets. 2012 , 13-29	
243	Protective effect of urantide against ischemia-reperfusion injury via protein kinase C and phosphatidylinositol 3'-kinase - Akt pathway. 2012 , 90, 637-45	15
242	Urotensin II protects ischemic reperfusion injury of hearts through ROS and antioxidant pathway. 2012 , 36, 199-205	14
241	Down-regulation of GABA(A) receptor via promiscuity with the vasoactive peptide urotensin II receptor. Potential involvement in astrocyte plasticity. 2012 , 7, e36319	9
240	The Molecules: Abnormal Vasculatures in the Splanchnic and Systemic Circulation in Portal Hypertension". 2012 ,	1
239	Urotensin upregulates transforming growth factor- β expression of asthma airway through ERK-dependent pathway. 2012 , 364, 291-8	10
238	In vitro siRNA-mediated knockdown of the UT receptor: implications of density on the efficacy of a range of UT ligands. 2012 , 385, 651-6	

- 237 Endothelial dysfunction in the regulation of cirrhosis and portal hypertension. **2012**, 32, 199-213 119
- 236 Angiotensin II mediates urotensin II expression by hypoxia in cultured cardiac fibroblast. **2012**, 42, 17-26 12
- 235 Urotensin II prevents cardiomyocyte apoptosis induced by doxorubicin via Akt and ERK. **2012**, 680, 88-94 24
- 234 Urocontrin, a novel UT receptor ligand with a unique pharmacological profile. **2012**, 83, 608-15 21
- 233 Characterization of the true ortholog of the urotensin II-related peptide (URP) gene in teleosts. **2012**, 177, 205-12 17
- 232 Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies in humans and in a mouse model of diabetes. **2013**, 56, 1155-65 27
- 231 The differential extraction and immunoluminometric assay of Urotensin II and Urotensin-related peptide in heart failure. **2013**, 40, 72-6 18
- 230 Impact of gene/genome duplications on the evolution of the urotensin II and somatostatin families. **2013**, 188, 110-7 25
- 229 An atlas and functional analysis of G-protein coupled receptors in human islets of Langerhans. **2013**, 139, 359-91 139
- 228 The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. **2013**, 170, 1459-581 509
- 227 Urotensin inhibition with palosuran could be a promising alternative in pulmonary arterial hypertension. **2013**, 36, 405-12 12
- 226 Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotides. **2013**, 21, 27-43 63
- 225 Urotensin II receptor (UTR) exists in hyaline chondrocytes: a study of peripheral distribution of UTR in the African clawed frog, *Xenopus laevis*. **2013**, 185, 44-56 13
- 224 Urotensin II exerts antiapoptotic effect on NRK-52E cells through prostacyclin-mediated peroxisome proliferator-activated receptor alpha and Akt activation. **2013**, 381, 168-74 7
- 223 Daily rhythms of urotensin I and II gene expression and hormone secretion in the caudal neurosecretory system of the euryhaline flounder (*Platichthys flesus*). **2013**, 188, 189-95 15
- 222 Identification of transmembrane domain 3, 4 & 5 residues that contribute to the formation of the ligand-binding pocket of the urotensin-II receptor. **2013**, 86, 1584-93 7
- 221 Urotensin II-induced collagen synthesis in cultured smooth muscle cells from rat aortic media and a possible involvement of transforming growth factor- β /Smad2/3 signaling pathway. **2013**, 182, 53-8 15
- 220 Deconstruction of sulfonamide inhibitors of the urotensin receptor (UT) and design and synthesis of benzylamine and benzylsulfone antagonists. **2013**, 23, 2177-80 7

219	Helicates, Peptide-Helicates and Metal-Assisted Stabilization of Peptide Microstructures. 2013 , 275-302	1
218	New insight into the binding mode of peptides at urotensin-II receptor by Trp-constrained analogues of PSU and urantide. 2013 , 19, 293-300	10
217	Urotensin-II promotes vascular smooth muscle cell proliferation through store-operated calcium entry and EGFR transactivation. 2013 , 100, 297-306	61
216	Update on the urotensinergic system: new trends in receptor localization, activation, and drug design. 2012 , 3, 174	19
215	Effect of KIOM-79 on Diabetes-Induced Myocardial Fibrosis in Zucker Diabetic Fatty Rats. 2013 , 2013, 547653	6
214	Urotensin II and the kidney. 2013 , 22, 107-12	6
213	Pressor and renal regional hemodynamic effects of urotensin II in neonatal pigs. 2013 , 217, 317-26	7
212	H ₂ S inhibits the activation of hepatic stellate cells and downregulates the expression of urotensin II. 2013 , 43, 670-8	4
211	Endothelial nitric oxide synthase (eNOS) (Glu298Asp) and urotensin II (UTS2 S89N) gene polymorphisms in preeclampsia: prediction and correlation with severity in Egyptian females. 2013 , 32, 292-303	6
210	Urotensin-II Ligands: An Overview from Peptide to Nonpeptide Structures. 2013 , 2013, 979016	11
209	Urotensin II Peptides. 2013 , 957-965	1
208	Urotensin Peptides. 2013 , 1437-1442	
207	In Silico Search for Biologically Active Peptides. 2013 , 1743-1748	1
206	Urotensin II inhibits skeletal muscle glucose transport signaling pathways via the NADPH oxidase pathway. 2013 , 8, e76796	9
205	Urotensin-II system in genetic control of blood pressure and renal function. 2013 , 8, e83137	10
204	Effects of Urotensin II Receptor Antagonist, GSK1440115, in Asthma. 2013 , 4, 54	10
203	Urotensin II induces interleukin 8 expression in human umbilical vein endothelial cells. 2014 , 9, e90278	16
202	Urotensin II promotes atherosclerosis in cholesterol-fed rabbits. 2014 , 9, e95089	12

201	Urotensin II inhibits doxorubicin-induced human umbilical vein endothelial cell death by modulating ATF expression and via the ERK and Akt pathway. 2014 , 9, e106812	10
200	Up-regulation of urotensin II and its receptor contributes to human hepatocellular carcinoma growth via activation of the PKC, ERK1/2, and p38 MAPK signaling pathways. 2014 , 19, 20768-79	13
199	A comparison of assay performance between the calcium mobilization and the dynamic mass redistribution technologies for the human urotensin receptor. 2014 , 12, 361-8	6
198	Lycopene Inhibits Urotensin-II-Induced Cardiomyocyte Hypertrophy in Neonatal Rat Cardiomyocytes. 2014 , 2014, 724670	9
197	Chemical Feature-Based Molecular Modeling of Urotensin-II Receptor Antagonists: Generation of Predictive Pharmacophore Model for Early Drug Discovery. 2014 , 2014, 1-16	4
196	Urotensin-II receptor is over-expressed in colon cancer cell lines and in colon carcinoma in humans. 2014 , 44, 285-94	19
195	Blocking the urotensin II receptor pathway ameliorates the metabolic syndrome and improves cardiac function in obese mice. 2014 , 28, 1210-20	9
194	RGS2 regulates urotensin II-induced intracellular Ca ²⁺ elevation and contraction in glomerular mesangial cells. 2014 , 229, 502-11	20
193	Biased signaling regulates the pleiotropic effects of the urotensin II receptor to modulate its cellular behaviors. 2014 , 28, 5148-62	31
192	Urotensin II inhibited the proliferation of cardiac side population cells in mice during pressure overload by JNK-LRP6 signalling. 2014 , 18, 852-62	12
191	UTS2R gene polymorphisms are associated with fatty acid composition in Japanese beef cattle. 2014 , 85, 499-505	8
190	Dynamic expression pattern of corticotropin-releasing hormone, urotensin I and II genes under acute salinity and temperature challenge during early development of zebrafish. 2014 , 40, 1877-86	3
189	Circulating levels of the vasoactive peptide urotensin II in patients with acute coronary syndrome and stable coronary artery disease. 2014 , 55, 151-7	12
188	Urantide conformation and interaction with the urotensin-II receptor. 2014 , 347, 185-92	8
187	Ull and UT in grouper: cloning and effects on the transcription of hormones related to growth control. 2014 , 220, 35-48	12
186	Angiotensin II and the JNK pathway mediate urotensin II expression in response to hypoxia in rat cardiomyocytes. 2014 , 220, 233-46	13
185	Synthesis and SAR of thieno[3,2-b]pyridinyl urea derivatives as urotensin-II receptor antagonists. 2014 , 24, 5832-5835	9
184	Concordant localization of functional urotensin II and urotensin II-related peptide binding sites in the rat brain: Atypical occurrence close to the fourth ventricle. 2014 , 522, 2634-49	3

183	Therapeutic implications of peptide interactions with G-protein-coupled receptors in diabetic vasculopathy. 2014 , 211, 20-35	7
182	Molecular evolution of GPCRs: Somatostatin/urotensin II receptors. 2014 , 52, T61-86	42
181	Identification of transmembrane domain 1 & 2 residues that contribute to the formation of the ligand-binding pocket of the urotensin-II receptor. 2014 , 92, 280-8	4
180	Predicted ligands for the human urotensin-II G protein-coupled receptor with some experimental validation. 2014 , 9, 1732-43	5
179	Urotensin II increases foam cell formation by repressing ABCA1 expression through the ERK/NF- κ B pathway in THP-1 macrophages. 2014 , 452, 998-1003	22
178	Palosuran treatment effective as bosentan in the treatment model of pulmonary arterial hypertension. 2014 , 37, 1280-8	7
177	Lead optimization of PSU and urantide: discovery of novel potent ligands at the urotensin-II receptor. 2014 , 57, 5965-74	18
176	Can early myocardial infarction-related deaths be diagnosed using postmortem urotensin receptor expression levels?. 2014 , 10, 395-400	1
175	Contractile responses to rat urotensin II in resting and depolarized basilar arteries. 2014 , 70, 193-9	8
174	Effects of urotensin II on intracellular pH regulation in cultured human internal mammary artery smooth muscle cells. 2014 , 56, 173-82	6
173	Urotensin II (U-II), a novel cyclic peptide, possibly associated with the pathophysiology of osteoarthritis. 2014 , 54, 159-61	1
172	No-reflow phenomenon: pathophysiology, diagnosis, prevention, and treatment. A review of the current literature and future perspectives. 2014 , 65, 180-9	51
171	Expression of Urotensin II During Focal Cerebral Ischemic in Diabetic Rats. 2014 , 41, 498-503	3
170	An investigation into the expression and mechanism of action of urotensin II in chronic pressure-overloaded rat hearts. 2015 , 12, 6626-34	4
169	Urotensin II as a novel marker for portal hypertension and bleeding varices. 2015 , 5, 54-59	
168	1,3,4-Thiadiazol-2-amine Derivatives as Urotensin-II Receptor (UT) Antagonists. 2015 , 36, 2549-2552	3
167	Comparative distribution and in vitro activities of the urotensin II-related peptides URP1 and URP2 in zebrafish: evidence for their colocalization in spinal cerebrospinal fluid-contacting neurons. 2015 , 10, e0119290	23
166	Urotensin II Protects Cardiomyocytes from Apoptosis Induced by Oxidative Stress through the CSE/H2S Pathway. 2015 , 16, 12482-98	12

165	Autocrine Human Urotensin II Enhances Macrophage-Derived Foam Cell Formation in Transgenic Rabbits. 2015 , 2015, 843959	9
164	An investigation into the origin of the biased agonism associated with the urotensin II receptor activation. 2015 , 21, 392-9	15
163	Urotensin-II receptor stimulation of cardiac L-type Ca ²⁺ channels requires the β subunits of Gi/o-protein and phosphatidylinositol 3-kinase-dependent protein kinase C α isoform. 2015 , 290, 8644-55	20
162	The orally active urotensin receptor antagonist, KR36676, attenuates cellular and cardiac hypertrophy. 2015 , 172, 2618-33	19
161	The role of the UTS2 gene polymorphisms and plasma Urotensin-II levels in breast cancer. 2015 , 36, 4427-32	9
160	Signaling switch of the urotensin II vasosactive peptide GPCR: prototypic chemotaxic mechanism in glioma. 2015 , 34, 5080-94	12
159	Urotensin II upregulates migration and cytokine gene expression in leukocytes of the African clawed frog, <i>Xenopus laevis</i> . 2015 , 216, 54-63	7
158	Unravelling osteoarthritis-related synovial fibrosis: a step closer to solving joint stiffness. 2015 , 54, 1954-63	45
157	International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, urotensin II-related peptide, and their receptor: from structure to function. 2015 , 67, 214-58	58
156	An atlas of G-protein coupled receptor expression and function in human subcutaneous adipose tissue. 2015 , 146, 61-93	50
155	Blockade of Urotensin II Receptor Prevents Vascular Dysfunction. 2016 , 24, 523-8	5
154	Renal Urotensin II System Plays Roles in the Regulation of Blood Pressure in Dahl Salt-Resistant Rat. 2016 , 2016, 9146870	1
153	Urotensin-II Receptor Antagonist SB-710411 Protects Rat Heart against Ischemia-Reperfusion Injury via RhoA/ROCK Pathway. 2016 , 11, e0146094	18
152	The Urotensin II System and Carotid Atherosclerosis: A Role in Vascular Calcification. 2016 , 7, 149	11
151	Urotensin II. 2016 , 88-e11-5	
150	Increased expression of urotensin II is associated with poor prognosis in hepatocellular carcinoma. 2016 , 12, 4961-4968	4
149	Pathogenesis of Macrovascular Complications in Diabetes. 2016 , 599-628	1
148	Role of urotensin II in advanced glycation end product-induced extracellular matrix synthesis in rat proximal tubular epithelial cells. 2016 , 38, 1831-1838	4

147	Benzo[b]thiophene-2-carboxamide derivatives as potent urotensin-II receptor antagonists. 2016 , 26, 4684-4686	6
146	A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension. 2016 , 40, 196-202	19
145	Urotensin II Induces ER Stress and EMT and Increase Extracellular Matrix Production in Renal Tubular Epithelial Cell in Early Diabetic Mice. 2016 , 41, 434-49	22
144	Urolinin: The First Linear Peptidic Urotensin-II Receptor Agonist. 2016 , 59, 10100-10112	3
143	Effects of peripherally administered urotensin II and arginine vasotocin on the QT interval of the electrocardiogram in trout. 2016 , 183-184, 53-60	1
142	Aging and Erectile Dysfunction. 2016 , 4, 63-73	26
141	Role of UTS2 gene in the genetic susceptibility to atrial fibrillation in the Chinese population. 2016 , 92, 201-7	1
140	Expression levels of urotensin II are associated with endoplasmic reticulum stress in patients with severe preeclampsia. 2016 , 30, 129-35	7
139	The role of neuropeptides in adverse myocardial remodeling and heart failure. 2017 , 74, 2019-2038	11
138	Genetic polymorphisms of rs2890565 Ser89Asn in cardiac hypertrophy in Chinese Han population. 2017 , 93, 406-413	2
137	Conformation and Dynamics of Human Urotensin II and Urotensin Related Peptide in Aqueous Solution. 2017 , 57, 298-310	8
136	Purification and characterization of bioactive peptides RYamide and CCHamide in the kuruma shrimp <i>Marsupenaeus japonicus</i> . 2017 , 246, 321-330	13
135	Age-Related Reduction of Contractile Responses to Urotensin II Is Seen in Aortas from Wistar Rats but Not from Type 2 Diabetic Goto-Kakizaki Rats. 2017 , 20, 134-145	3
134	Urotensin II inhibitor eases neuropathic pain by suppressing the JNK/NF- κ B pathway. 2017 , 232, 165-174	15
133	Expressions of irisin and urotensin II and their relationships with blood pressure in patients with preeclampsia. 2017 , 39, 460-467	19
132	Plasma Urotensin II levels in children and adolescents with chronic kidney disease: a single-centre study. 2017 , 18, 113	3
131	Urotensinergic system genes in experimental subarachnoid hemorrhage. 2017 , 41, 468-474	
130	The role of water-soluble meconium subfraction and lipid-soluble meconium subfraction on the superior mesenteric artery vasoconstriction in chick embryos. 2017 , 52, 481-483	3

129	Comparison of two competitive enzyme immunoassay kits for quantification of plasma Urotensin-II in rats. 2017 , 38, 247-256	
128	Urotensin 2 in Kawasaki disease pathogenesis. 2017 , 82, 1048-1055	1
127	Insight into the role of urotensin II-related peptide tyrosine residue in UT activation. 2017 , 144, 100-107	7
126	Design, Synthesis, and Biological Assessment of Biased Allosteric Modulation of the Urotensin II Receptor Using Achiral 1,3,4-Benzotriazepin-2-one Turn Mimics. 2017 , 60, 9838-9859	11
125	Urotensin II Exerts Pressor Effects By Stimulating Renin And Aldosterone Synthase Gene Expression. 2017 , 7, 13876	3
124	Pulmonary artery hypertension: pertinent vasomotorial cytokines. 2017 , 28, 1-7	2
123	The potential of novel peptides in the management of children with Congenital Heart Disease: Above and beyond the BNP. 2017 , 45, 95-100	1
122	The Relation Between No-Reflow Phenomenon and Complete Blood Count Parameters. 2017 , 68, 381-388	25
121	Urotensinergic system genes in experimental subarachnoid hemorrhage. 2017 , 41, 468-474	
120	Indole-2-carboxamide Derivatives as Potent Urotensin-II Receptor (UT) Antagonists. 2017 , 38, 1109-1112	1
119	Urotensin II promotes aldosterone expression in rat aortic adventitial fibroblasts. 2018 , 17, 2921-2928	2
118	UTS2 (urotensin 2). 2017 ,	
117	Acute Effect of Central Administration of Urotensin II on Baroreflex and Blood Pressure in Conscious Normotensive Rabbits. 2017 , 8, 110	
116	NADPH Oxidases, Angiogenesis, and Peripheral Artery Disease. 2017 , 6,	8
115	The G Protein-Coupled Receptor UT of the Neuropeptide Urotensin II Displays Structural and Functional Chemokine Features. 2017 , 8, 76	14
114	Central and Peripheral Effects of Urotensin II and Urotensin II-Related Peptides on Cardiac Baroreflex Sensitivity in Trout. 2017 , 11, 51	1
113	Effects of a Long-Acting Formulation of Octreotide on Patients with Portal Hypertension. 2017 , 2017, 3943210	0
112	Neurohormonal Blockade in Heart Failure. 2017 , 3, 19-24	27

111	Diabetic macular oedema: under-represented in the genetic analysis of diabetic retinopathy. 2018 , 96 Suppl A111, 1-51	5
110	Inhibition of A-Type K ⁺ Channels by Urotensin-II Induces Sensory Neuronal Hyperexcitability Through the PKC/ERK Pathway. 2018 , 159, 2253-2263	8
109	The role of urotensin-II and its receptors in sepsis-induced lung injury under diabetic conditions. 2018 , 818, 457-469	19
108	Cilia-driven cerebrospinal fluid flow directs expression of urotensin neuropeptides to straighten the vertebrate body axis. 2018 , 50, 1666-1673	54
107	Urotensin-II gene rs228648 polymorphism associated with the risk of diabetes mellitus. 2018 , 38,	2
106	Oxidative/antioxidative status, lymphocyte DNA damage, and urotensin-2 receptor level in patients with migraine attacks. 2018 , 14, 367-374	20
105	Multiple-Dose Pharmacokinetics, Pharmacodynamics, and Safety of the Urotensin-II Receptor Antagonist Palosuran in Healthy Male Subjects. 2018 , 102, 339-346	3
104	Discovery of New Allosteric Modulators of the Urotensinergic System through Substitution of the Urotensin II-Related Peptide (URP) Phenylalanine Residue. 2018 , 61, 8707-8716	8
103	The Protective Effect of Total Flavones from Planch. on Myocardial Ischemia/Reperfusion Injury and Its Underlying Mechanism. 2018 , 2018, 6139372	5
102	Chronic Urotensin-II Administration Improves Whole-Body Glucose Tolerance in High-Fat Diet-Fed Mice. 2019 , 10, 453	4
101	Dynamic Expression and Regulation of Urotensin I and Corticotropin-Releasing Hormone Receptors in Ovary of Olive Flounder. 2019 , 10, 1045	4
100	Novel insights into the role of urotensin II in cardiovascular disease. 2019 , 24, 2170-2180	6
99	A Pilot Study Using a Multistaged Integrated Analysis of Gene Expression and Methylation to Evaluate Mechanisms for Evening Fatigue in Women Who Received Chemotherapy for Breast Cancer. 2019 , 21, 142-156	6
98	Urotensin-related gene transcripts mark developmental emergence of the male forebrain vocal control system in songbirds. 2019 , 9, 816	3
97	Urotensin II Induces Mice Skeletal Muscle Atrophy Associated with Enhanced Autophagy and Inhibited Irisin Precursor (Fibronectin Type III Domain Containing 5) Expression in Chronic Renal Failure. 2019 , 44, 479-495	5
96	Urotensin II receptor antagonist reduces hepatic resistance and portal pressure through enhanced eNOS-dependent HSC vasodilatation in CCl ₄ -induced cirrhotic rats. 2019 , 13, 398-408	5
95	The Application of Network Structure Analysis in the Study of Disease Mechanisms. 2019 ,	
94	UTS2B Defines a Novel Enteroendocrine Cell Population and Regulates GLP-1 Secretion Through SSTR5 in Male Mice. 2019 , 160, 2849-2860	2

93	Oxidative parameters, oxidative DNA damage, and urotensin-II in schizoaffective disorder patients. 2019 , 29, 151-157	2
92	Synthesis and SAR of 5-aryl-furan-2-carboxamide derivatives as potent urotensin-II receptor antagonists. 2019 , 29, 577-580	1
91	Urotensin II in the development and progression of chronic kidney disease following \square nephrectomy in the rat. 2019 , 104, 421-433	5
90	Natural and synthetic peptides in the cardiovascular diseases: An update on diagnostic and therapeutic potentials. 2019 , 662, 15-32	14
89	The relationship between urotensin II and insulin resistance in women with gestational diabetes mellitus. 2019 , 18, 91-97	5
88	A Novel and Highly Potent Urotensin II Receptor Antagonist Inhibits Urotensin II-Induced Pressure Response in Mice. 2019 , 73, 15-21	6
87	Urotensin receptors as a new target for CLP induced septic lung injury in mice. 2019 , 392, 135-145	18
86	Cerebrovascular effects of endothelin-1 investigated using high-resolution magnetic resonance imaging in healthy volunteers. 2020 , 40, 1685-1694	9
85	Functional effects of urotensin-II on intracellular pH regulators in human radial artery smooth muscle cells. 2020 , 126, 170236	1
84	Urantide Improves Cardiac Function, Modulates Systemic Cytokine Response, and Increases Survival in A Murine Model of Endotoxic Shock. 2020 , 54, 574-582	3
83	Microinjection of urotensin II into the pedunculopontine tegmentum leads to an increase in the consumption of sweet tastants. 2020 , 215, 112775	
82	Study of the association between Urotensin 2 (p.T21M and p.S89N) variants and breast cancer in Egyptian patients. 2020 , 20, 100789	
81	Identification of novel Urotensin-II receptor antagonists with potent inhibition of U-II induced pressor response in mice. 2020 , 886, 173391	2
80	Insights into the Molecular Determinants Involved in Urocontrin and Urocontrin A Action. 2020 , 11, 1717-1722	0
79	Identification and signaling characterization of four urotensin II receptor subtypes in the western clawed frog, <i>Xenopus tropicalis</i> . 2020 , 299, 113586	3
78	Association of resistin (rs3745367) and urotensin II (rs228648 and rs2890565) gene polymorphisms with risk of type 2 diabetes mellitus in Indian population. 2020 , 47, 9489-9497	5
77	Bioinformatic analysis and functional predictions of selected regeneration-associated transcripts expressed by zebrafish microglia. 2020 , 21, 870	3
76	Potential Therapeutic Value of Urotensin II Receptor Antagonist in Chronic Kidney Disease and Associated Comorbidities. 2020 , 374, 24-37	2

75	Microinjection of urotensin II into the rostral ventrolateral medulla increases sympathetic vasomotor tone via the GPR14/ERK pathway in rats. 2020 , 43, 765-771	1
74	Targeting of G-protein coupled receptors in sepsis. 2020 , 211, 107529	2
73	Activation of a nerve injury transcriptional signature in airway-innervating sensory neurons after lipopolysaccharide-induced lung inflammation. 2020 , 318, L953-L964	9
72	Association between Plasma Urotensin II and Risk of Hypertension: Findings from a Prospective Study. 2020 , 2020, 3284769	
71	The urotensin II receptor antagonist DS37001789 ameliorates mortality in pressure-overload mice with heart failure. 2020 , 6, e03352	2
70	Abstracts and Citations. 2020 , 60, 482-492	
69	Commentary: Molecular pathogenesis of aortic stenosis: Will the puzzle pieces ever fit together?. 2019 ,	
68	Urotensin II, urotensin-related peptide, and their receptor in aortic valve stenosis. 2019 ,	4
67	Urotensin II'in İnsan Osteoblast Hücrelerinde Enflamasyonla İlişkili Rolü	0
66	An Academic Clinician's Road Map to Hypertension Genomics: Recent Advances and Future Directions MMXX. 2021 , 77, 284-295	4
65	Targeting the Urotensin II/UT G Protein-Coupled Receptor to Counteract Angiogenesis and Mesenchymal Hypoxia/Necrosis in Glioblastoma. 2021 , 9, 652544	2
64	Characterization of four urotensin II receptors (UTS2Rs) in chickens. 2021 , 138, 170482	2
63	Conserved role of the urotensin II receptor 4 signalling pathway to control body straightness in a tetrapod. 2021 , 11, 210065	2
62	Urotensin II Induces Cardiac Fibrosis through the TGF- β /Smad Signaling Pathway during the Development of Cardiac Hypertrophy. 2021 , 62, 1135-1144	0
61	Urotensin II induces activation of NLRP3 and pyroptosis through calcineurin in cardiomyocytes. 2021 , 144, 170609	1
60	Discovering Networks of Interdependent Features in High-Dimensional Problems. 2016 , 285-304	7
59	Design, Synthesis and Conformational Analysis of Human Urotensin II (U-II) Analogues with Lactam Bridge. 2001 , 630-631	1
58	Vasoactive Molecules and the Kidney. 2012 , 384-420	2

57	Blocking of urotensin receptors as new target for treatment of carrageenan induced inflammation in rats. 2016 , 82, 35-43	14
56	Urotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol.	5
55	Central cardiovascular action of urotensin II in spontaneously hypertensive rats. 2003 , 26, 839-45	40
54	Association analysis of urotensin II gene (UTS2) and flanking regions with biochemical parameters related to insulin resistance. 2011 , 6, e19327	12
53	Endogenous urotensin II selectively modulates erectile function through eNOS. 2012 , 7, e31019	12
52	Urotensin II in invertebrates: from structure to function in <i>Aplysia californica</i> . 2012 , 7, e48764	23
51	Urotensin II: an inflammatory cytokine. 2019 ,	7
50	Kidney is in trouble with mediators. 2010 , 10 Suppl 1, S29-36	2
49	Effects of urotensin II and its specific receptor antagonist urantide on rat vascular smooth muscle cells. 2013 , 13, 78-83	4
48	Oncogenic effects of urotensin-II in cells lacking tuberous sclerosis complex-2. 2016 , 7, 61152-61165	5
47	Association between vasoactive peptide urotensin II in plasma and cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a potential therapeutic target. 2018 , 1-11	2
46	Urotensin II-induced insulin resistance is mediated by NADPH oxidase-derived reactive oxygen species in HepG2 cells. 2016 , 22, 5769-79	9
45	A Novel Urotensin II Receptor Antagonist, KR-36996 Inhibits Smooth Muscle Proliferation through ERK/ROS Pathway. 2017 , 25, 308-314	7
44	A new therapeutic approach to erectile dysfunction: urotensin-II receptor high affinity agonist ligands. 2015 , 17, 81-5	2
43	Effect of urotensin II on apolipoprotein B100 and apolipoprotein A-I expression in HepG2 cell line. 2014 , 3, 22	2
42	Urotensin II-related peptide (Urp) is expressed in motoneurons in zebrafish, but is dispensable for locomotion in larva. 2021 , 146, 170675	1
41	Blutdruck und Blutdruckregulation. 2001 , 3-17	
40	Neural and Humoral Control. 2002 , 323-340	

- 39 Application of peptides as reaction specific probes for the automated mass spectrometry-assisted enzyme screening (MES). *Journal of Electrophoresis*, **2005**, 49, 29-34 0.8
- 38 Physiological Function of G Protein-Coupled Receptors (GPCRs) and Research Trends for Orphan GPCRs. *Journal of Korean Endocrine Society*, **2005**, 20, 185
- 37 Fish Peptides. **2006**, 1515-1519
- 36 Novel Markers of Hemodynamic Stress. **2006**, 427-447
- 35 Urotensin-II Receptor. **2007**, 1-5
- 34 Role of Novel Biomarkers in Chronic Kidney Disease: Urotensin II. **2010**, 299-308
- 33 The Pathogenesis of Macrovascular Complications Including Atherosclerosis in Diabetes. 635-656 1
- 32 . *Comparative Endocrinology*, **2013**, 39, 172-174 0
- 31 Circulating Vasoactive Peptide Urotensin II and Relationships with Cardiovascular Disease. **2015**, 1-23
- 30 Effect of Different Peptides. **2015**, 1-45
- 29 Effect of Different Peptides. **2016**, 513-553
- 28 Circulating Vasoactive Peptide Urotensin II and Relationships with Cardiovascular Disease. **2016**, 153-175
- 27 Homology Modelling of Urotensin-2 Receptor (UTS2R): Potential Target for Human Pharmacotherapy. *Journal of the Chosun Natural Science*, **2016**, 9, 185-189
- 26 Vasoactive Factors and Blood Pressure in Children. **2017**, 1-19
- 25 Vasoactive Factors and Blood Pressure in Children. **2018**, 27-45
- 24 Effect of Pro-Inflammatory Cytokine IL-1 β on Urotensin II Gene Expression in Human Lung Cancer Cells. *Konuralp Tip Dergisi*, 354-359
- 23 Activation of a nerve injury transcriptional signature in airway-innervating sensory neurons after LPS induced lung inflammation.
- 22 Identifying Circulating Urotensin II and Urotensin II-Related Peptide-Generating Enzymes in the Human Plasma Fraction Cohn IV-4. *Journal of Proteome Research*, **2021**, 20, 5368-5378 5.6

21	Orphan Neuropeptides and the Regulation of Food Intake. 2008 , 3-19		
20	Roles of Vasoactive Agents in Macrophage Foam Cell Formation and Atherosclerosis. 2008 , 89-96		
19	De-Orphanizing GPCRs and Drug Development. 2005 , 389-401		
18	Birth Weight Standard Deviation Score is a Significant Determinant of Serum Urotensin-II Levels at Term-Equivalent Age in Preterm Infants. <i>American Journal of Perinatology</i> , 2020 ,	3.3	
17	Association of three polymorphisms in the gene coding for endothelin-1 with essential hypertension, overweight and smoking. <i>Experimental and Clinical Cardiology</i> , 2002 , 7, 201-4		2
16	Genetic polymorphisms of rs2890565 Ser89Asn in coronary heart disease and myocardial infarction in Chinese population. <i>International Journal of Clinical and Experimental Pathology</i> , 2018 , 11, 2125-2136	1.4	
15	[Changes in serum chromogranin A and urotensin II levels in children with chronic heart failure]. <i>Chinese Journal of Contemporary Pediatrics</i> , 2017 , 19, 313-317	0.8	
14	The Role of Urotensin-II in Obesity and Metabolic Syndrome in Pediatric Population.. <i>Children</i> , 2022 , 9,	2.8	
13	The network map of urotensin-II mediated signaling pathway in physiological and pathological conditions.. <i>Journal of Cell Communication and Signaling</i> , 2022 , 1	5.2	1
12	Increased circulating concentrations of bioactive PTH 1-84 in patients with heart failure. <i>Journal of Endocrinological Investigation</i> , 2012 , 35, 987-91	5.2	3
11	Vasoactive Factors and Blood Pressure in Children. 2022 , 1-18		
10	Inhibition of U-II / UT signaling ameliorates cystitis-associated bladder hyperactivity by targeting the RhoA /Rho-kinase pathway. <i>Kaohsiung Journal of Medical Sciences</i> ,	2.4	
9	Urotensin II-Related Peptides, Urp1 and Urp2, Control Zebrafish Spine Morphology.		
8	Zebrafish: an important model for understanding scoliosis. 2022 , 79,		1
7	Globular adiponectin-mediated vascular remodeling by affecting the secretion of adventitial-derived tumor necrosis factor- α induced by urotensin II. 2022 , 23, 1014-1027		0
6	Urotensin II-related peptides, Urp1 and Urp2, control zebrafish spine morphology. 11,		0
5	Combination of Docking-Based and Pharmacophore-Based Virtual Screening Identifies Novel Agonists That Target the Urotensin Receptor. 2022 , 27, 8692		0
4	Vasoactive Factors and Blood Pressure in Children. 2023 , 41-58		0

- 3 2-{N-[(2,4,5-trichlorophenoxy) acetyl]-N-methylamino}-3-pyrrolidinepropanamide analogs as potential antagonists of Urotensin II receptor. 1-8 ○
- 2 Protective effect of urotensin II receptor antagonist urantide and exercise training on doxorubicin-induced cardiotoxicity. **2023**, 13, ○
- 1 Urotensin II Enhances Advanced Aortic Atherosclerosis Formation and Delays Plaque Regression in Hyperlipidemic Rabbits. **2023**, 24, 3819 ○